Ligand Pharmaceuticals IncNASDAQ:LGND
- LAST PRICE84.0700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots83.0000/ 3
- Ask / Lots93.0000/ 3
- Open / Previous Close0.0000 / 84.0700
- Day Range---
- 52 Week Range
- Volume4
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LGND |
|---|---|---|
| 09:32 ET | 3943 | 87.34 |
| 09:38 ET | 100 | 87.53 |
| 09:48 ET | 300 | 87.2 |
| 09:50 ET | 319 | 87.27 |
| 09:54 ET | 200 | 87.28 |
| 09:56 ET | 200 | 87.02 |
| 09:57 ET | 145 | 87.005 |
| 09:59 ET | 800 | 86.75 |
| 10:01 ET | 103 | 86.6775 |
| 10:03 ET | 600 | 86.28 |
| 10:06 ET | 200 | 86.3 |
| 10:08 ET | 100 | 86.43 |
| 10:12 ET | 350 | 86.0279 |
| 10:14 ET | 200 | 86 |
| 10:15 ET | 420 | 85.665 |
| 10:19 ET | 150 | 85.79 |
| 10:21 ET | 100 | 85.445 |
| 10:24 ET | 275 | 85.57 |
| 10:26 ET | 245 | 85.7652 |
| 10:28 ET | 300 | 85.84 |
| 10:32 ET | 100 | 85.895 |
| 10:35 ET | 431 | 85.91 |
| 10:39 ET | 2500 | 86.63 |
| 10:42 ET | 200 | 86.59 |
| 10:44 ET | 605 | 86.63 |
| 10:46 ET | 395 | 86.35 |
| 10:50 ET | 300 | 86.02 |
| 10:51 ET | 300 | 85.69 |
| 10:55 ET | 250 | 85.44 |
| 11:00 ET | 100 | 85.43 |
| 11:02 ET | 200 | 85.555 |
| 11:08 ET | 100 | 85.83 |
| 11:11 ET | 192 | 85.4543 |
| 11:13 ET | 425 | 85.8 |
| 11:15 ET | 700 | 85.465 |
| 11:24 ET | 250 | 85.3107 |
| 11:27 ET | 225 | 85.0385 |
| 11:31 ET | 300 | 85.1 |
| 11:33 ET | 445 | 85.18 |
| 11:40 ET | 100 | 85.18 |
| 11:45 ET | 600 | 84.8 |
| 11:47 ET | 184 | 84.5828 |
| 11:58 ET | 100 | 84.505 |
| 12:00 ET | 100 | 84.64 |
| 12:03 ET | 107 | 84.5238 |
| 12:07 ET | 600 | 84.6407 |
| 12:14 ET | 100 | 84.62 |
| 12:21 ET | 300 | 84.85 |
| 12:25 ET | 300 | 84.73 |
| 12:27 ET | 400 | 84.39 |
| 12:34 ET | 100 | 84.43 |
| 12:38 ET | 200 | 84.275 |
| 12:39 ET | 741 | 84.0605 |
| 12:41 ET | 640 | 84.1041 |
| 12:52 ET | 120 | 84 |
| 12:54 ET | 100 | 84.01 |
| 12:56 ET | 1781 | 84.31 |
| 12:57 ET | 1095 | 84.555 |
| 12:59 ET | 395 | 84.69 |
| 01:10 ET | 100 | 84.875 |
| 01:21 ET | 200 | 84.82 |
| 01:30 ET | 100 | 84.98 |
| 01:33 ET | 300 | 84.75 |
| 01:35 ET | 206 | 84.76 |
| 01:44 ET | 200 | 84.61 |
| 01:50 ET | 462 | 84.795 |
| 01:53 ET | 300 | 84.83 |
| 01:55 ET | 100 | 84.59 |
| 02:06 ET | 100 | 84.7 |
| 02:08 ET | 100 | 84.825 |
| 02:09 ET | 110 | 84.735 |
| 02:20 ET | 100 | 84.85 |
| 02:26 ET | 100 | 84.96 |
| 02:29 ET | 200 | 84.76 |
| 02:33 ET | 100 | 84.66 |
| 02:36 ET | 700 | 84.8 |
| 02:40 ET | 700 | 84.61 |
| 02:42 ET | 500 | 84.61 |
| 02:44 ET | 200 | 84.59 |
| 02:45 ET | 100 | 84.615 |
| 02:47 ET | 900 | 84.77 |
| 02:51 ET | 100 | 84.655 |
| 02:54 ET | 100 | 84.66 |
| 02:58 ET | 100 | 84.46 |
| 03:00 ET | 300 | 84.475 |
| 03:12 ET | 100 | 84.45 |
| 03:14 ET | 100 | 84.305 |
| 03:16 ET | 200 | 84.37 |
| 03:21 ET | 200 | 84.26 |
| 03:23 ET | 100 | 84.33 |
| 03:25 ET | 100 | 84.2 |
| 03:27 ET | 125 | 84.2 |
| 03:30 ET | 200 | 84.17 |
| 03:32 ET | 393 | 84.1405 |
| 03:34 ET | 100 | 84.225 |
| 03:36 ET | 200 | 84.215 |
| 03:39 ET | 100 | 84.14 |
| 03:41 ET | 1180 | 84.27 |
| 03:43 ET | 320 | 84.36 |
| 03:45 ET | 100 | 84.47 |
| 03:48 ET | 2473 | 84.5 |
| 03:50 ET | 1270 | 84.26 |
| 03:52 ET | 300 | 84.35 |
| 03:54 ET | 100 | 84.335 |
| 03:56 ET | 1045 | 84.285 |
| 03:57 ET | 671 | 84.095 |
| 03:59 ET | 21190 | 84.07 |
May 8, 2024
DJ Ligand Pharmaceuticals Price Target Maintained With a $144.00/Share by HC Wainwright & Co., from 6:43AM ET on Wednesday May 08, 2024 by Dow Jones
6:43AM ET on Wednesday May 08, 2024 by Dow Jones
May 7, 2024
*DJ Ligand Pharmaceuticals 1Q EPS $4.75 >LGND, from 4:00PM ET on Tuesday May 07, 2024 by Dow Jones
4:00PM ET on Tuesday May 07, 2024 by Dow JonesLigand Reports First Quarter 2024 Financial Results, from 4:00PM ET on Tuesday May 07, 2024 by Dow Jones
4:00PM ET on Tuesday May 07, 2024 by Dow JonesLigand and Agenus Enter Into $100 Million Royalty Financing Agreement, from 7:30AM ET on Tuesday May 07, 2024 by Dow Jones
7:30AM ET on Tuesday May 07, 2024 by Dow Jones
Apr 23, 2024
Press Release: Ligand to Report First Quarter 2024 Financial Results on May 7, 2024, from 8:40AM ET on Tuesday Apr 23, 2024 by Dow Jones
8:40AM ET on Tuesday Apr 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ligand Pharmaceuticals Inc | 1.5B | 16.1x | -12.71% |
Avadel Pharmaceuticals PLC | 1.6B | -9.0x | --- |
Tarsus Pharmaceuticals Inc | 1.4B | -8.1x | --- |
Ocular Therapeutix Inc | 872.7M | -5.2x | --- |
SIGA Technologies Inc | 529.9M | 6.8x | -28.78% |
Harrow Inc | 427.1M | -16.2x | --- |
Company Information
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Contact Information
- Headquarters
- 555 Heritage Drive, Suite 200JUPITER, FL, United States 33458
- Phone
- 858-550-7500
- Fax
- 302-636-5454
Executives
- Non-Executive Independent Chairman of the Board
- John Kozarich
- President, Chief Operating Officer
- Matthew Korenberg
- Chief Executive Officer, Director
- Todd Davis
- Chief Financial Officer
- Octavio Espinoza
- Chief Legal Officer
- Andrew Reardon
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.5B |
|---|---|
Revenue (TTM) | $118.3M |
Shares Outstanding | 18.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.04 |
EPS | $5.23 |
Book Value | $39.92 |
P/E Ratio | 16.1x |
Price/Sales (TTM) | 12.8 |
Price/Cash Flow (TTM) | 11.4x |
Operating Margin | -2.01% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
